Evidence map: what has been studied, and how strong is it?

Semax has a long clinical footprint in Russia and a much thinner footprint in Western trial registries and English-language journals. This page maps where evidence exists, what kind of evidence it is, and what visitors should understand about limits - without sales language and without telling anyone what to take.

Educational only. Not medical advice. Not a recommendation to use Semax for any condition.

Snapshot

Russian clinical-use contexts

In Russian practice and drug listings, Semax has been discussed or registered in contexts that include:

• Ischemic stroke and other cerebrovascular syndromes (acute period and rehabilitation phases)
• Cognitive complaints linked to cerebrovascular disease or workload/attention studies in volunteers
• Optic nerve pathology (partial atrophy; glaucomatous optic neuropathy with normalized intraocular pressure; vascular / inflammatory optic neuropathies in combination protocols)

Semax appears on Russian Vital and Essential Drugs lists in some years (frequently cited for ~2011–2012 listings). That regulatory status is not the same thing as global regulatory approval or as high-certainty efficacy proof by contemporary Western evidence standards.

Stroke and cerebrovascular evidence

What exists

• Early clinical reports (1990s–2000s) from Russian stroke groups (including work associated with Gusev / Skvortsova / Myasoedov collaborations) described neurological improvement when Semax was added to standard care. Many full texts remain Russian-language; English readers often see abstracts only.
• Gusev et al., 2018 (Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova): 110 patients after ischemic stroke, early vs late rehabilitation subgroups, with/without Semax courses. Reported higher plasma brain-derived neurotrophic factor (BDNF), better Barthel index trajectories, and motor-scale improvements associated with Semax and with higher BDNF. Design note: not a classic large placebo-controlled multicenter RCT as summarized in English abstracts.
• DOI: 10.17116/jnevro20181183261-68
• Shmonin et al., 2018 meta-analysis (Bulletin of Rehabilitation Medicine): searched PubMed + eLibrary; 8 stroke studies (n ≈ 654) met a custom quality bar; only 3 (n ≈ 181) shared matching endpoints for pooling. Authors reported National Institutes of Health Stroke Scale (NIHSS) / Rankin / Rivermead advantages favoring Semax in moderate–severe subgroups, and explicitly concluded that a powerful multicenter double-blind study is still needed, with standardized designs for future meta-analysis.
• https://journals.eco-vector.com/2078-1962/article/view/609445

Preclinical support: animals, not patients

Rodent ischemia / photothrombosis models report smaller lesions, better avoidance learning, neurotrophin gene induction, and immune/vascular gene-expression shifts (Romanova; Dmitrieva; Medvedeva and related Institute of Molecular Genetics (IMG) RAS groups). These are hypothesis-generating, not substitutes for human RCTs.

Quality flags visitors should notice

• Frequent adjunct use (Semax + standard stroke care), which complicates attribution
• Variable blinding, randomization, and outcome timing across older Russian reports
• High heterogeneity when studies are pooled (the Shmonin meta-analysis itself shows large I² in several forest plots)
• English-language critical reviews (e.g., ADDF Cognitive Vitality) judge well-conducted published human literature as lacking, even while acknowledging Russian clinical use

Cognitive / “healthy volunteer” and imaging evidence

• Kaplan et al., 1996 (Neuroscience Research Communications): early human report of nootropic-like activity (attention / short-term memory / EEG-type markers) after Semax in volunteers - historically important, small by modern standards.
• Lebedeva et al., 2018: resting-state fMRI pilot in healthy subjects; Semax vs placebo altered default-mode network signal (rostral subcomponent). Useful mechanistic/brain-systems clue; not a clinical cognition outcome trial.
• Kolomin et al. (2013) summarize additional Russian cognitive/EEG work that is hard to audit fully from English secondary sources alone.

Visitor takeaway: Signals exist that Semax can change brain physiology and task performance in small studies. That is not the same as robust evidence for everyday cognitive enhancement or for dementia prevention. ADDF’s researcher brief states there is no clinical evidence for Alzheimer’s disease and little evidence for cognition in healthy aging.

Optic nerve evidence

Russian ophthalmology papers (mostly abstracts on PubMed) describe Semax as an adjunct neuroprotective agent:

• Polunin et al., 2000: optic nerve disease / partial atrophy; intranasal vs endonasal electrophoresis vs control-type comparison; authors reported better visual acuity, visual-field extent, and electrophysiologic indices when Semax was added. PMID: 10741256
• Kurysheva et al., 2001: glaucomatous optic neuropathy with normalized ophthalmic tone; electrophysiology / computer methods favored Semax-containing regimens over “traditional” neuroprotection alone. PMID: 11569188
• Later combination protocols (e.g., Semax + transcutaneous neurostimulation or broader physiotherapy stacks) report visual-field or light-sensitivity gains; these designs often confound Semax with other interventions.

Quality flags: small cohorts; limited Western replication; combination therapy common; long-term hard endpoints (sustained blindness prevention) not established in large independent trials.

Western replication gaps

What “Western gap” usually means here:

1. Regulatory: Semax is used as a prescription peptide medicine in Russia/CIS contexts; it is not a U.S. Food and Drug Administration (FDA)- or European Medicines Agency (EMA)-approved drug for stroke, cognition, or optic neuropathy.
2. Trial infrastructure: Independent large, prospectively registered, double-blind, multicenter RCTs with English full-data packages remain scarce. Shmonin’s team noted (as of their 2015–2018 search window) no ClinicalTrials.gov Semax stroke registrations and no English-journal clinical stroke RCTs in their PubMed sweep - while Russian eLibrary held many mentions.
3. Critical appraisals: Independent Western briefs (ADDF Cognitive Vitality) emphasize that published well-conducted human studies are lacking, despite preclinical breadth and Russian clinical experience.
4. Grey-market noise: Online “research peptide” vendors publish marketing summaries that often overstate effect sizes and invent precision (exact NIHSS deltas, NNT figures) not always traceable to primary papers. Prefer PubMed / journal PDFs over vendor blogs.

What visitors should understand about study limitations

Reading Semax papers carefully

• Language and access bias. Much primary clinical detail lives in Russian journals. Abstracts travel; methods and raw tables often do not. That inflates confidence for English-only readers.
• Adjunct designs. If everyone gets modern stroke care and some also get Semax, benefits may be real, small, or confounded - hard to know without strong blinding and allocation concealment.
• Surrogate vs. hard outcomes. Plasma BDNF, EEG, or short NIHSS shifts are interesting. They are not the same as long-term independence, cognition, or vision preservation proven at scale.
• Heterogeneous “Semax” protocols. Concentration (0.1% vs 1%), course length, and combination therapies differ across papers - another reason pooling is fragile.
• Publication ecosystem. Positive local experience + national formulary listing can coexist with incomplete global evidence. Both facts can be true at once.
• Mechanism ≠ proof of benefit. BDNF / tropomyosin receptor kinase B (TrkB) and monoamine findings in rats (see How Semax works) do not certify clinical efficacy in any indication.
• Safety literature in English is thin. Commonly mentioned local nasal effects and limited systemic signals appear in secondary summaries; large modern pharmacovigilance packages in Western databases are not the main story. Absence of English AE tables is not proof of perfect safety.

What we don’t know

Evidence gaps

• Whether Semax would meet contemporary Phase III standards for acute ischemic stroke if run as a large, international, double-blind trial
• Dose–response and timing windows that generalize outside Russian protocols (no dosing advice here - just noting the gap)
• Independent replication of optic-nerve functional gains
• Effects (or lack of effects) in Alzheimer’s disease and healthy cognitive aging
• Long-term outcomes and rare adverse events in diverse populations
• How much of reported benefit is BDNF-mediated in humans

Origin note

Peer-reviewed history places Semax with Myasoedov / Ashmarin programs at the Institute of Molecular Genetics (late 1970s design work; mid-1980s synthesis/intensive study). Online “KGB ops” origin claims are not established. See How Semax works for the mechanism-side origin table.

Sources

1. Gusev EI, et al. The efficacy of Semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(3):61–68. https://doi.org/10.17116/jnevro20181183261-68
2. Shmonin AA, Verbickaya EV, Soloveva LN, Malceva MN, Melnikova EV. Meta-analysis: Semax effectiveness in the acute period of stroke. Bulletin of Rehabilitation Medicine. 2018;17(2):81–88. https://journals.eco-vector.com/2078-1962/article/view/609445
3. Polunin GS, Nurieva SM, Baiandin DL, Sheremet NL, Andreeva LA. [Evaluation of therapeutic effect of new Russian drug Semax in optic nerve disease]. Vestn Oftalmol. 2000;116(1):15–18. PMID: 10741256 · https://pubmed.ncbi.nlm.nih.gov/10741256/
4. Kurysheva NI, Shpak AA, Ioĭleva EE, et al. [Semax in the treatment of glaucomatous optic neuropathy in patients with normalized ophthalmic tone]. Vestn Oftalmol. 2001;117(4):5–8. PMID: 11569188 · https://pubmed.ncbi.nlm.nih.gov/11569188/
5. Kaplan AY, Kochetova AG, Nezavibathko VN, Rjasina TV, Ashmarin IP. Synthetic ACTH analogue Semax displays nootropic-like activity in humans. Neurosci Res Commun. 1996;19(2):115–123.
6. Kolomin T, Shadrina M, Slominsky P, Limborska S, Myasoedov N. A new generation of drugs: synthetic peptides based on natural regulatory peptides. Neuroscience & Medicine. 2013;4:223–252. https://doi.org/10.4236/nm.2013.44035
7. Ashmarin IP, Nezavibat'ko VN, Myasoedov NF, et al. [A nootropic adrenocorticotropin analog 4-10-semax (15 years experience in its design and study)]. Zh Vyssh Nerv Deiat Im I P Pavlova. 1997;47(2):420–430. PMID: 9173745
8. Dolotov OV, et al. Semax… regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117:54–60. https://doi.org/10.1016/j.brainres.2006.07.108 · PMID: 16996037 (preclinical mechanism often cited alongside clinical BDNF observations)
9. Dmitrieva VG, et al. Semax and Pro-Gly-Pro activate transcription of neurotrophins… after focal brain ischemia in rats. Cell Mol Neurobiol. 2010;30:71–79. PMID: 19633950
10. Medvedeva EV, et al. Semax… genome-wide transcriptional analysis (focal ischemia). BMC Genomics. 2014;15:228. https://doi.org/10.1186/1471-2164-15-228
11. Alzheimer’s Drug Discovery Foundation. Semax: Cognitive Vitality Report (for researchers). https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Semax-Cognitive-Vitality-For-Researchers.pdf
12. WHO / Russian Federation Vital and Essential Drugs List materials (2012 listing frequently cited in secondary sources; verify year-specific annexes).

Weakly sourced vendor claims (precise NIHSS point gains, NNT figures, “Phase III Western approval”) were not used as evidence here.